Extract from the Register of European Patents

EP About this file: EP2485724

EP2485724 - Sulfonamides for the prevention of diabetes [Right-click to bookmark this link]
Former [2012/33]SULFONAMIDES FOR THE PREVENTION OF DIABETES
[2015/31]
StatusNo opposition filed within time limit
Status updated on  16.12.2016
Database last updated on 31.03.2026
Most recent event   Tooltip16.12.2016No opposition filed within time limitpublished on 18.01.2017  [2017/03]
Applicant(s)For all designated states
Dompé farmaceutici s.p.a.
Via S. Martino Della Battaglia 12
20122 Milano / IT
[2015/14]
Former [2012/33]For all designated states
Dompé S.p.A.
Località Campo di Pile snc
67100 L'Aquila (AQ) / IT
Inventor(s)01 / PIEMONTI, Lorenzo
Diabetes Research Institute (HSR-DRI)
San Raffaele Scientific Institute
Via Olgettina 60
I-20132 Milano / IT
02 / DAFFONCHIO, Luisa
c/o Dompé S.p.A.
Località Campo di Pile snc
I-67100 L`Aquila AQ / IT
03 / ALLEGRETTI, Marcello
c/o Dompé S.p.A.
Località Campo di Pile snc
I-67100 L`Aquila AQ / IT
 [2012/33]
Representative(s)Pistolesi, Roberto, et al
Dragotti & Associati Srl
Via Nino Bixio, 7
20129 Milano / IT
[N/P]
Former [2016/06]Mauri, Elisabetta Maria Ester, et al
PGA S.r.l.
Via Mascheroni, 31
20145 Milano / IT
Former [2012/33]Sutto, Luca, et al
Ponzellini, Gioia e Associati S.r.l. Via Mascheroni, 31
20145 Milano / IT
Application number, filing date10768898.806.10.2010
[2016/06]
WO2010EP64920
Priority number, dateEP2009017236506.10.2009         Original published format: EP 09172365
[2012/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011042465
Date:14.04.2011
Language:EN
[2011/15]
Type: A1 Application with search report 
No.:EP2485724
Date:15.08.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 14.04.2011 takes the place of the publication of the European patent application.
[2012/33]
Type: B1 Patent specification 
No.:EP2485724
Date:10.02.2016
Language:EN
[2016/06]
Search report(s)International search report - published on:EP14.04.2011
ClassificationIPC:A61K31/185, A61P3/10
[2012/33]
CPC:
A61K31/185 (EP,KR,US); A61K31/18 (KR); C07C311/51 (KR,US);
A61P1/18 (EP); A61P3/00 (EP); A61P3/10 (EP);
A61P43/00 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/33]
Extension statesBA30.03.2012
ME30.03.2012
TitleGerman:Sulfonamide zur Diabetesprävention[2015/31]
English:Sulfonamides for the prevention of diabetes[2015/31]
French:Sulfonamides pour la prévention du diabète[2015/31]
Former [2012/33]SULFONAMIDE ZUR VORBEUGUNG VON DIABETES
Former [2012/33]SULFONAMIDES FOR THE PREVENTION OF DIABETES
Former [2012/33]SULFONAMIDES POUR LA PRÉVENTION DU DIABÈTE
Entry into regional phase30.03.2012National basic fee paid 
30.03.2012Designation fee(s) paid 
30.03.2012Examination fee paid 
Examination procedure30.03.2012Examination requested  [2012/33]
16.11.2012Amendment by applicant (claims and/or description)
26.01.2015Despatch of a communication from the examining division (Time limit: M04)
03.06.2015Reply to a communication from the examining division
05.08.2015Communication of intention to grant the patent
03.12.2015Fee for grant paid
03.12.2015Fee for publishing/printing paid
03.12.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  26.01.2015
Opposition(s)11.11.2016No opposition filed within time limit [2017/03]
Fees paidRenewal fee
23.10.2012Renewal fee patent year 03
31.10.2013Renewal fee patent year 04
27.10.2014Renewal fee patent year 05
21.10.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inby applicant  MAY, CURR DIABETES REV, vol. 4, no. 2, pages 110 - 121
   AUTOIMMUNE REV, vol. 5, no. 6, July 2006 (2006-07-01), pages 424 - 428
   REMINGTON: "The Science and Practice of Pharmacy", LIPPINCOTT WILLIAMS AND WILKINS
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.